NO912864L - Stedsspesifikk in vivo-aktivering av terapeutiske forbindelser - Google Patents

Stedsspesifikk in vivo-aktivering av terapeutiske forbindelser

Info

Publication number
NO912864L
NO912864L NO91912864A NO912864A NO912864L NO 912864 L NO912864 L NO 912864L NO 91912864 A NO91912864 A NO 91912864A NO 912864 A NO912864 A NO 912864A NO 912864 L NO912864 L NO 912864L
Authority
NO
Norway
Prior art keywords
prodrug according
anthracycline
group
prodrug
negatively charged
Prior art date
Application number
NO91912864A
Other languages
English (en)
Other versions
NO912864D0 (no
Inventor
Reinhard Bredehorst
Chong-Ho Kim
Richard Mccabe
Nicholas Pomato
Carl-Wilhelm Vogel
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23161497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO912864(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of NO912864D0 publication Critical patent/NO912864D0/no
Publication of NO912864L publication Critical patent/NO912864L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1. Aktivator-målsøkingsdel-konjugat, karakterisert ved at det omfatter lysozym som aktivator og et humant monoklonalt antistoff eller et fragment av dette som målsøkingsdel. 2. Prodroge, karakterisert ved at den omfatter et anti- kreftmiddel som bærer et spaltbart molekyl som hindrer celle- opptak. 3. Prodroge ifølge krav 2, karakterisert ved at den omfatter et anti- kreftmiddel som er derivatisert med et kitinoligomer-avstands- materiale. 4. Prodroge ifølge krav 3, karakterisert ved at antikreftmidlet er et antracyklin. 5. Prodroge ifølge krav 4, karakterisert ved at kitinoligomer-avstands- materialet er festet via en aminogruppe på et sted valgt fra gruppen som består av C13-karbonylstedet på antracyklinet og sukkerdelen av antracyklinet. 6. Prodroge ifølge krav 5, karakterisert ved at kitinoligomer-derivatet inneholder (GlcNAc)n, hvor n er 1-10, som bærer negativt ladede grupper og en reaktiv gruppe som gir mulighet for kovalent festing til antracyklinet. 7. Prodroge ifølge krav 6, karakterisert ved at de negativt ladede grupper representerer sulfonater, fosfater, karboksylater eller fosfonater. 8. Prodroge ifølge krav 6, karakterisert ved at antallet negativt ladede grupper er fra l til 10. 9. Prodroge ifølge krav 3, karakterisert ved at kitinoligoroer-avstands- materialet er bundet kovalent til drogen via en aktiv gruppe valgt blant disulfid-, tioester-, imid-, halogen-, amin-, karboksyl-, ester-, tiol- og alkoholgrupper. 10. Prodroge ifølge krav 6, karakterisert ved at den reaktive gruppe er valgt blant disulfid-, tioester-, imid-, halogen-, amin-, karboksyl-, ester-, tiol- og alkoholgrupper.
NO91912864A 1989-01-23 1991-07-22 Stedsspesifikk in vivo-aktivering av terapeutiske forbindelser NO912864L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30099989A 1989-01-23 1989-01-23
PCT/US1990/000503 WO1990007929A1 (en) 1989-01-23 1990-01-23 Site specific in-vivo activation of therapeutic drugs

Publications (2)

Publication Number Publication Date
NO912864D0 NO912864D0 (no) 1991-07-22
NO912864L true NO912864L (no) 1991-09-19

Family

ID=23161497

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91912864A NO912864L (no) 1989-01-23 1991-07-22 Stedsspesifikk in vivo-aktivering av terapeutiske forbindelser

Country Status (12)

Country Link
EP (1) EP0454783B1 (no)
JP (1) JP3273608B2 (no)
KR (1) KR0185967B1 (no)
AT (1) ATE123414T1 (no)
AU (1) AU648015B2 (no)
CA (1) CA2025899A1 (no)
DE (1) DE69019959T2 (no)
DK (1) DK0454783T3 (no)
ES (1) ES2075893T3 (no)
FI (1) FI97692C (no)
NO (1) NO912864L (no)
WO (1) WO1990007929A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
US5474772A (en) * 1989-08-02 1995-12-12 Cobe Laboratories, Inc. Method of treatment with medical agents
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
EP0505357B1 (en) * 1989-12-11 1999-03-10 Immunomedics, Inc. Method for antibody targeting of diagnostic or therapeutic agents
SE9100142L (sv) 1991-01-17 1992-07-18 Bengt Sandberg En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
WO1994001137A1 (en) * 1992-07-06 1994-01-20 Hybritech Incorporated Method for delivery of cytotoxic agents and components thereof
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
CA2205091A1 (en) * 1994-12-23 1996-07-04 Zeneca Limited Chemical compounds
BR9610050A (pt) 1995-08-16 1999-10-13 Zeneca Ltd Conjugado,sitemas de dois componentes combinados destinados a uso em um hospedeiro, compostos ou um sal destes famaceuticamente aceitavel,enzima,sequencia de polinucleotìdeos e de02 nucleotìdeos,vetor, célula hospedeira,processos de producão de uma enzima e de um conjugado e de tratamento de célulasneoplásticas em um hospedeiro,composicão farmaceutica e plasmìdeo
DK0795334T3 (da) * 1996-03-12 2006-06-06 Sanofi Aventis Deutschland Nye prodrugs til behandling af tumorer og betændelsessygdomme
PL229108B1 (pl) * 2014-08-22 2018-06-29 Celther Polska Spolka Z Ograniczona Odpowiedzialnoscia Sposób wydzielania i oczyszczania estrów chityny (mono-, di‑podstawionych) oraz kopoliestrów chityny z mieszanin poreakcyjnych
EP3970752A1 (en) * 2020-09-17 2022-03-23 Merck Patent GmbH Molecules with solubility tag and related methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067774A (en) * 1971-05-14 1978-01-10 Syva Company Compounds for enzyme amplification assay
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
LU85581A1 (fr) * 1984-10-10 1986-06-11 Smb Lab Ensembles d'anticorps monoclonaux diriges contre la lactoferrine humaine et le lysozyme humain
JPS62138496A (ja) * 1985-12-11 1987-06-22 Ihara Chem Ind Co Ltd キチンオリゴマ−の製造方法
ATE137674T1 (de) * 1987-07-02 1996-05-15 Akzo Nobel Nv Von mca 16-88 erkanntes antigen
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies

Also Published As

Publication number Publication date
KR0185967B1 (ko) 1999-05-01
KR910700072A (ko) 1991-03-13
DE69019959T2 (de) 1995-10-05
AU5039790A (en) 1990-08-13
DK0454783T3 (da) 1995-10-16
EP0454783A1 (en) 1991-11-06
DE69019959D1 (de) 1995-07-13
FI913511A0 (fi) 1991-07-22
FI97692B (fi) 1996-10-31
NO912864D0 (no) 1991-07-22
WO1990007929A1 (en) 1990-07-26
CA2025899A1 (en) 1990-07-24
ATE123414T1 (de) 1995-06-15
AU648015B2 (en) 1994-04-14
EP0454783B1 (en) 1995-06-07
FI97692C (fi) 1997-02-10
EP0454783A4 (en) 1992-01-15
JPH04503068A (ja) 1992-06-04
JP3273608B2 (ja) 2002-04-08
ES2075893T3 (es) 1995-10-16

Similar Documents

Publication Publication Date Title
AU671247B2 (en) Paclitaxel derivatives
Mellado et al. Preparation and biological activity of taxol acetates
AU669218B2 (en) Prodrugs, their preparation and use as pharmaceuticals
DE69637383T2 (de) Cytotoxinkonjugate umfassend dipeptide
JP5392956B2 (ja) 担体−薬物複合体
US5760072A (en) Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy
Luczkowiak et al. Pseudosaccharide functionalized dendrimers as potent inhibitors of DC-SIGN dependent Ebola pseudotyped viral infection
AU614532B2 (en) Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EA003790B1 (ru) Соединение сдлс и способ его измерения
EP2911696A1 (en) Drug-protein conjugates
KR0185967B1 (ko) 치료용 약물의 부위 특이적 생체내 활성작용
Yang et al. Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody–drug conjugation
Wei et al. A photoactivated prodrug
Ahangarpour et al. Late-stage desulfurization enables rapid and efficient solid-phase synthesis of cathepsin-cleavable linkers for antibody–drug conjugates
Suzawa et al. Synthesis and HPLC analysis of enzymatically cleavable linker consisting of poly (ethylene glycol) and dipeptide for the development of immunoconjugate
JPH0654681A (ja) レシチン化スーパーオキシドディスムターゼ及びそれを有効成分とする医薬
JPH07316205A (ja) シクロデキストリン誘導体
White Jr [48] Thiolation
KR101472316B1 (ko) 프로드러그
ES2292750T3 (es) Procedimiento para preparar lipido ii.
KR20030011306A (ko) 지질 ⅱ의 제조 방법
Yan et al. The use of aminoglycoside derivatives to study the mechanism of aminoglycoside 6′-N-acetyltransferase and the role of 6′-NH2 in antibacterial activity
CA2114629C (en) Receptor conjugates for targeting antibiotics to bacteria
SAWADA et al. Studies on the β-lysine peptide. IV. Preparation of semi-synthetic racemomycins and their antimicrobial activities
LaTour Understanding transglycosylase inhibition: Chlorobiphenyl vancomycin and moenomycin A as targets for synthesis and modification